Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Moffitt Cancer Center, Hospital Universitario 12 De Octubre, Sarah Cannon, Tennessee Oncology, Dana-Farber Cancer Institute, Oregon Health & Science University, Yale Cancer Center, Heidelberg University, National Center for Tumor Diseases, University Hospital Heidelberg, Memorial Sloan Kettering Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Duke Medical Center, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Vanderbilt University, Vanderbilt-Ingram Cancer Center, Carolinas Medical Center, Levine Cancer Institute, Emory University, University of Glasgow, Royal Marsden Hospital, Helsinki University Hospital, University of Helsinki, Goethe University Frankfurt, University Hospital Frankfurt, Krankenhaus Nordwest, The University of Texas MD Anderson Cancer Center, Bristol-Myers Squibb (United States)